Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. J of Skin [Internet]. 2020 Jan. 28 [cited 2025 Apr. 19];4(1):S2. Available from: https://skin.dermsquared.com/skin/article/view/801